Podcasts about cardiac

New research shows that people with untreated sleep apnea experience a sharp nighttime drop in blood vessel function driven by the circadian system, increasing vulnerability to heart attacks and other cardiac events In a tightly controlled sleep-lab study, participants' arteries showed their worst ability to dilate around 3:00 a.m., revealing an 82% decline in vascular function during the biological night This impairment persisted even after adjusting for blood flow, sleep quality, and apnea severity, confirming the circadian system — not behavior or breathing events — directly weakens vascular health at night The findings help explain why people with sleep apnea experience more nighttime cardiac events, contrasting with the general population's morning peak in heart attacks and sudden cardiac death Researchers emphasize that understanding circadian timing may help refine cardiovascular treatments for sleep apnea patients, including optimizing medication schedules to enhance nighttime vascular protection

In this episode, the CardioNerds (Dr. Natalie Tapaskar, Dr. Jenna Skowronski, and Dr. Shazli Khan) discuss the process of heart transplantation from the initial donor selection to the time a patient is discharged with Dr. Dave Kaczorowski and Dr. Jason Katz. We dissect a case where we understand criteria for donor selection, the differences between DBD and DCD organ donors, the choice of vasoactive agents in the post-operative period, complications such as cardiac tamponade, and the choice of immunosuppression in the immediate post-operative period. Most importantly, we highlight the importance of multi-disciplinary teams in the care of transplant patients. Audio editing for this episode was performed by CardioNerds Intern, Dr. Julia Marques Fernandes. Enjoy this Circulation 2022 Paths to Discovery article to learn about the CardioNerds story, mission, and values. CardioNerds Heart Success Series PageCardioNerds Episode PageCardioNerds AcademyCardionerds Healy Honor Roll CardioNerds Journal ClubSubscribe to The Heartbeat Newsletter!Check out CardioNerds SWAG!Become a CardioNerds Patron! Pearls When thinking about donor selection, you need to consider how much physiologic stress your recipient can tolerate, and this may guide your selection of “higher risk” or “lower risk” donors.   The use of DCD donors has increased the potential donor pool and shortened waitlist times with very similar perioperative outcomes to DBD transplantation.  Post-operative critical care management rests on a fundamental principle to apply as much inotropic/vasoactive therapy as needed to achieve some reasonable physiologic hemostasis, and then getting “the heck out of the way!” There are no standard regimens as practices vary across centers, but rest on providing adequate RV support, maintaining AV synchrony, and early resuscitation.   The RV is fickle and doesn't take a joke too well. RV dysfunction post-transplant is important to watch for, and it can be transient or require aggressive support. Don't miss assessing for cardiac tamponade which can require surgical evacuation- “where there's space, that space can be filled with fluid.”   Induction immunosuppression post-transplant varies across centers, but some considerations for use may include (1) high sensitization of the patient, (2) high risk immunologic donor-recipient matching, and (3) recipient renal dysfunction to provide a calcineurin inhibitor (CNI) sparing regimen long term.  Management of heart transplant patients is a multi-disciplinary effort that requires coordination amongst heart failure/transplant cardiologists, cardiac surgeons, anesthesiologists, pathology/immunologists and a slew of ancillary services. Without a dynamic and collaborative team, successful cardiac transplantation could not be possible.  Notes Notes: Notes drafted by Dr. Natalie Tapaskar  What are the basic components of donor heart selection? In practicality, it can be a very inexact science, but we use some basic selection criteria such as: (1) size matching (2) ischemic time (3) donor graft function (4) immunologic compatibility (5) age of the potential donor and recipient (6) severity of illness of the recipient (7) regional variation in donor availability When thinking about accepting older donors (>50 years old), we ideally would screen for donor coronary disease and try to keep ischemic times as short as possible. We may accept an older donor for a recipient who is highly sensitized, which leaves a smaller potential donor pool. There is no clear consensus on size matching, but the predicted heart mass is most used. We are generally more comfortable oversizing than under-sizing donor hearts. Serial echocardiography is important in potential donors as initially reduced ejection fractions can improve on repeat testing, and these organs should not be disregarded automatically. For recipients who are more surgically complex, (i.e. multiple prior sternotomies or complex anatomy), it's probably preferable to avoid older donors with some graft dysfunction and favor donors with shorter ischemic times. What is the difference between DBD and DCD? DBD is donation after brain death- these donors meet criteria for brain death. Uniform Determination of Death Act 1980: the death of an individual is The irreversible cessation of circulatory and respiratory functions or The irreversible cessation of all functions of the entire brain, including those of the brain stem DCD is donation after circulatory death- donation of the heart after confirming that circulatory function has irreversibly ceased. Only donors in category 3 of the Maastricht Classification of DCD donors are considered for DCD donations: anticipated circulatory arrest (planned withdrawal of life-support treatment). DCD hearts can be procured via direct procurement or normothermic regional perfusion (NRP). The basic difference is the way the hearts are assessed, either on an external circuit or in the donor body. For the most complex recipient, DCD may not be utilized at some centers due to concern for higher rates of delayed graft function, but this is center specific and data is still evolving. What are some features surgeons consider when procuring the donor heart? Visual assessment of the donor heart is key in DBD or NRP cases. LV function may be hard to assess, but visually the RV can be inspected. Palpation of the coronary arteries is important to assess any calcifications or abnormalities. Ventricular arrhythmias at the time of procurement may be concerning. Key considerations in the procurement process: (1) Ensuring the heart remains decompressed at all times and doesn't become distended (2) adequate cardioplegia delivery (3) aorta is cross-clamped properly all the way across the vessel (4) avoiding injury to adjacent structures during procurement What hemodynamic parameters should we monitor and what vasoactive agents are used peri-heart transplant? There is no consensus regarding vasoactive agent use post-transplant and practice varies across institutions. Some commonly seen regimens may include: (1) AAI pacing around 110 bpm to support RV function and preserve AV synchrony (2) inotropic agents such as epinephrine and dobutamine to support RV function (3) pulmonary vasodilators such as inhaled nitric oxide to optimize RV afterload Early post-transplant patients tend to have low cardiac filling pressures and require preload monitoring and resuscitation initially. Slow weaning of inotropes as the patient shows signs of stable graft function and hemodynamics. RV dysfunction may manifest as elevated central venous pressure with low cardiac index or hypotension with reducing urine output. Optimize inotropic support, volume status, metabolic status (acidosis and hypoxia), afterload (pulmonary hypertension), and assess for cardiac tamponade. Tamponade requires urgent take-back to the operating room to evacuate material. Refractory RV failure requires mechanical circulatory support, with early consideration of VA-ECMO. Isolated RV MCS may be used in the right clinical context. Why do pericardial effusions/cardiac tamponade happen after transplant? They are not uncommon after transplant and can be due to: Inherent size differences between the donor and recipient (i.e. if the donor heart is much smaller than the recipient's original heart) Bleeding from suture lines and anastomoses, pacing wires, and cannulation sites Depending on the hemodynamic stability of the patient and the location of the effusion, these effusions may require urgent return to the OR for drainage/clot evacuation via reopening the sternotomy, mini thoracotomy, and possible pericardial windows. What are the basics of immunosuppression post-transplant? Induction immunosuppression is variably used and is center-specific. Considerations for using induction therapy may include: (1) high sensitization of the patient (2) younger patients or multiparous women with theoretically more robust immune systems (3) crossing of recipient antibodies with donor antigens (3) renal function to provide a CNI sparing regimen long term Some considerations for avoiding induction may include: (1) older age of the recipient (2) underlying comorbid conditions such as infections or frailty of the recipient What are expected activity restrictions post-transplant? Sternal precautions are important to maintain sternal wire integrity. Generally avoiding lifting >10 pounds in the first 4-12 weeks, no driving usually in the first 4 weeks, monitoring for signs and symptoms of wound infections, and optimizing nutrition and physical activity. Cardiac rehabilitation is incredibly important as soon as feasible. References Kharawala A , Nagraj S , Seo J , et al. Donation after circulatory death heart transplant: current state and future directions. Circ: Heart Failure. 2024;17(7). doi: 10.1161/circheartfailure.124.011678  Copeland H, Knezevic I, Baran DA, et al. Donor heart selection: Evidence-based guidelines for providers. The Journal of Heart and Lung Transplantation. 2023;42(1):7-29. doi:10.1016/j.healun.2022.08.030  Moayedifar R, Shudo Y, Kawabori M, et al. Recipient Outcomes With Extended Criteria Donors Using Advanced Heart Preservation: An Analysis of the GUARDIAN-Heart Registry. J Heart Lung Transplant. 2024;43(4):673-680. doi:10.1016/j.healun.2023.12.013  Kharawala A, Nagraj S, Seo J, et al. Donation After Circulatory Death Heart Transplant: Current State and Future Directions. Circ Heart Fail. 2024;17(7):e011678. doi:10.1161/CIRCHEARTFAILURE.124.011678  Copeland H, Hayanga JWA, Neyrinck A, et al. Donor heart and lung procurement: A consensus statement. J Heart Lung Transplant. 2020;39(6):501-517.

Dr. Centor discusses complications of cardiac implantable electronic devices with Dr. Peter Zimetbaum.

The Cardiac and Comeback kids come from behind again. Villa win ugly, Villa win when not creating much (0.6 XG) and Villa win at the weekend after another trip to Europe.Husband Rupert and Wife Verna discuss the following:That's 11 from 12, 14 from 16, 6 in a row Winning uglyAnother huge win - the machine rolls on Only 3 players had good games Some had real stinkers - Konsa, Cash, Mcginn, Onana and Watkins Is it sustainable? Can this continue Rogers carrying the team on his back The end of Watkins is approaching Incredibly fun being a Villa fun - enjoy it Hosted by Audiomeans. Visit audiomeans.fr/politique-de-confidentialite for more information.

27% Less Cardiac Death: The Cocoa Extract Study Explained Ep. 1271 DEC 2025A major randomized controlled trial, the COSMOS study, previously established a stunning statistic: older adults taking daily cocoa extract experienced a 27% reduction in cardiovascular disease death. However, the biological reason why remained unclear—until now. A new analysis published in Age and Ageing (Sept 2025) examined the bloodwork of 598 participants over two years. The researchers discovered that the cocoa extract (containing 500mg of flavanols) significantly reduced "inflammaging"—specifically lowering high-sensitivity C-reactive protein (hsCRP) by 8.4%. This reduction in chronic inflammation offers the "missing link" that explains the mechanism behind the massive 27% drop in cardiovascular mortality.3. Citations & Resources• Primary Study: Li, S., et al. "Effects of 2-year cocoa extract supplementation on inflammaging biomarkers in older US adults." Age and Ageing, 2025. Link to Article• Press Release: Mass General Brigham. "Study finds cocoa extract supplement reduced key marker of inflammation and aging." EurekAlert! Link to Press Release4. Disclaimers• "This information is for educational purposes only and should not be interpreted as medical advice."• "The study discussed was conducted on older adults (60+). Further research may be needed to confirm these findings in other populations."• "Always consult with a qualified healthcare professional before making any changes to your diet, supplement regimen, or treatment plan, especially if you have a medical condition or are taking medications."#CardiovascularHealth #CocoaExtract #27Percent #Inflammaging #LongevityResearchAlchepharma,Ralph Turchiano,citation,research,study,Cocoa extract,cardiovascular mortality,COSMOS trial,heart disease death prevention,hsCRP,inflammation mechanism,reduced cardiovascular mortality,flavanol benefits,life extension study,cardiovascular health,randomized controlled trial,systemic inflammation,C-reactive protein,nutrition science,heart protection,vascular health,immune modulation,interferon-gamma,heart health,longevity science

Episodio 7.42 de Las Cosas Que Hay Que Escuchar, en el cual nos preparamos para el fin de año mientras escuchamos la música de Carolina Durante, Il Maniscalco Maldestro, Seasick Steve, Cardiacs, Frank Zappa, Gary Numan, Suzanne Vega, Cult With No Name, Chris And Cosey, Rick Wakeman, Elio e le Storie Tese y Martinibomb. Y, obviamente, todo el delirio habitual de Saurio y las voces que lo atormentan. Si quieren convidar con un cafecito ☕, pueden hacerlo acá: https://cafecito.app/saurio

Angela talks to special guest Dr Darshan Shah, M.D, about the multifaceted world of longevity and health optimisation. They delve into essential biomarkers for assessing longevity, including inflammation levels, metabolic health, and cognitive function, while emphasising the importance of a holistic approach to well-being.  Dr. Shah also discusses the complexities surrounding LDL cholesterol, the significance of lifestyle factors like exercise and diet, and the role of hormone replacement therapy for women navigating menopause KEY TAKEAWAYS: Holistic Approach to Longevity: Longevity is not just about extending lifespan but also about enhancing health-span, which includes mental, physical, and emotional well-being Individualised Assessment of LDL: LDL cholesterol levels should be interpreted in the context of individual health Importance of Lifestyle Interventions: Lifestyle factors, including regular exercise, a balanced diet rich in whole foods, adequate sleep, and stress management, are foundational for improving health and reducing the risk of chronic diseases Role of Hormone Replacement Therapy: Hormone replacement therapy can significantly benefit women during perimenopause and menopause, improving metabolic biomarkers and overall health TIMESTAMPS AND KEY TOPICS: [00:04:05] LDL cholesterol's individual impact. [00:08:14] Cardiac risk biomarkers explained. [00:10:58] Lifestyle changes for plaque reduction. [00:23:08] Midlife metabolic health strategies. [00:24:37] Glucose spikes and metabolic health. [00:32:57] Liver detoxification myths. [00:35:13] Leaky gut and gut health. [00:45:48] Early cancer detection tools VALUABLE RESOURCES ⁠Join The High Performance Health Community⁠ ⁠Click here⁠ for discounts on all the products I personally use and recommend A BIG thank you to our sponsors who make the show possible ABOUT THE HOST Angela Foster is an award winning Nutritionist, Health & Performance Coach, Speaker and Host of the High Performance Health podcast. A former Corporate lawyer turned industry leader in biohacking and health optimisation for women, Angela has been featured in various media including Huff Post, Runners world, The Health Optimisation Summit, BrainTap, The Women's Biohacking Conference, Livestrong & Natural Health Magazine. Angela is the creator of BioSyncing®️ a blueprint for ambitious entrepreneurial women to biohack their health so they can 10X how they show up in their business and their family without burning out. CONTACT DETAILS ⁠Instagram⁠ ⁠Facebook⁠ ⁠LinkedIn⁠ Disclaimer: The High Performance Health Podcast is for general information purposes only and do not constitute the practice of professional or coaching advice and no client relationship is formed. The use of information on this podcast, or materials linked from this podcast is at the user's own risk. The content of this podcast is not intended to be a substitute for medical or other professional advice, diagnosis, or treatment. Users should seek the assistance of their medical doctor or other health care professional for before taking any steps to implement any of the items discussed in this podcast. This Podcast has been brought to you by Disruptive Media. ⁠https://disruptivemedia.co.uk/

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/RCF865. CME/AAPA credit will be available until December 8, 2026.Contemporary Insights on Diagnosing and Treating Transthyretin Cardiac Amyloidosis: How I Think, How I Treat In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from BridgeBio Pharma, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/RCF865. CME/AAPA credit will be available until December 8, 2026.Contemporary Insights on Diagnosing and Treating Transthyretin Cardiac Amyloidosis: How I Think, How I Treat In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from BridgeBio Pharma, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/RCF865. CME/AAPA credit will be available until December 8, 2026.Contemporary Insights on Diagnosing and Treating Transthyretin Cardiac Amyloidosis: How I Think, How I Treat In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from BridgeBio Pharma, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/RCF865. CME/AAPA credit will be available until December 8, 2026.Contemporary Insights on Diagnosing and Treating Transthyretin Cardiac Amyloidosis: How I Think, How I Treat In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from BridgeBio Pharma, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/RCF865. CME/AAPA credit will be available until December 8, 2026.Contemporary Insights on Diagnosing and Treating Transthyretin Cardiac Amyloidosis: How I Think, How I Treat In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from BridgeBio Pharma, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/RCF865. CME/AAPA credit will be available until December 8, 2026.Contemporary Insights on Diagnosing and Treating Transthyretin Cardiac Amyloidosis: How I Think, How I Treat In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from BridgeBio Pharma, Inc.Disclosure information is available at the beginning of the video presentation.

Carolina Panthers play by play commentator Anish Shroff joins the show and gives us the insider's perspective on the kitty cats. He speaks on Bryce Young's growth at quarterback, the Panthers' rollercoaster year, and what they need to do to win the NFC South.

Join Tina Baykaner, MD, MPH, HRS Digital Education Committee Vice-Chair, and her guests Mikhael F. El-Chami, MD, FHRS and  Devi G. Nair, MD, FHRS for this week's Lead episode. This article summarizes the worldwide experience retrieving chronically implanted active helix-fixation leadless ventricular pacemakers (the Aveir/Abbott platform) across regulatory clinical trials. The authors assess real-world feasibility, procedural techniques, success rates, and complications of retrieval after long dwell times, demonstrating that devices can be removed safely and effectively even years after implant—up to about 9 years in follow-up. Overall, chronic retrieval success remained high with a low rate of serious adverse events, supporting helix-fixation leadless systems as a manageable long-term pacing strategy when replacement or removal is needed.    Learning Objectives Explain the clinical indications for chronic retrieval of helix-fixation leadless pacemakers and how these differ from tine-fixation platforms.  Summarize the reported worldwide chronic retrieval success rates, implant-duration range, and key procedural or anatomic reasons for retrieval failure.  Identify practical procedural considerations (e.g., docking-button access, retrieval catheter use, imaging support) that improve the likelihood of safe long-term leadless pacemaker removal.   Article for Discussion: Worldwide Chronic Retrieval Experience of the Helix Fixation Leadless Cardiac Paccemaker   Article Authors and Podcast Contributors Article Authors Derek V. Exner, Reinoud E. Knops, Daniel J. Cantillon, Pascal Defaye, Rajesh Banker, Paul Friedman, Chris Hubbard, Stephanie M. Delgado, Anuradha Bulusu, and Vivek Y. Reddy Podcast Contributors Tina Baykaner, MD, MPH Mikhael F. El-Chami, MD, FHRS Devi G. Nair, MD, FHRS   Faculty Disclosures Host Disclosure(s): T. Baykaner •Honoraria/Speaking/Consulting: Volta Medical, Medtronic, Pacemate, Johnson and Johnson, Abbot Medical, Boston Scientific •Research: NIH   ​Contributor Disclosure(s):    M. El-Chami •Research: Medtronic, Boston Scientific •Speaking/Teaching/Consulting: Medtronic, Boston Scientific D. Nair •Speaking/Teaching/Consulting: Sieman's Healthineers •Membership on Advisory Committees: Biosense Webster, Medtronic, Abbott Medical, Boston Scientific   Staff Disclosure(s) (note: HRS staff are NOT in control of educational content. Disclosures are provided solely for full transparency to the learner): S. Sailor: No relevant financial relationships with ineligible companies to disclose.

Interview with Alfred E. Buxton, MD, and Marie-France Poulin, MD, authors of Mechanisms Underlying Alterations in Cardiac Conduction After Transcatheter Aortic Valve Replacement. Hosted by Kristen K. Patton, MD. Related Content: Mechanisms Underlying Alterations in Cardiac Conduction After Transcatheter Aortic Valve Replacement

Interview with Alfred E. Buxton, MD, and Marie-France Poulin, MD, authors of Mechanisms Underlying Alterations in Cardiac Conduction After Transcatheter Aortic Valve Replacement. Hosted by Kristen K. Patton, MD. Related Content: Mechanisms Underlying Alterations in Cardiac Conduction After Transcatheter Aortic Valve Replacement

With Edoardo Conte, Galeazzi Sant'Ambrogio Hospital IRCCS, Milano - Italy, Daniele Andreini, Galeazzi Sant'Ambrogio Hospital IRCCS, Milan - Italy and Davide Marchetti, Galeazzi Sant'Ambrogio Hospital IRCCS, Milano - Italy. Link to European Heart Journal paper Link to European Heart Journal editorial

In March 2022, Dr. Joseph Fraiman taped an internal call between FDA directors and physicians who were concerned about mRNA side effects in their patients – including the cardiac arrest and sudden death of a 7-year-old days after being injected with Pfizer's mRNA vaccine. “This was a top level meeting of directors,” Dr. Fraiman revealed to Ask Dr. Drew in Sept 2023. “This entire meeting terrified my entire work group.” The call – legally recorded by Dr. Fraiman – included FDA Director Dr. Peter Marks, Dr. Peter Doshi, Dr. Celia Witten, Dr. Sarah Walinsky, Dr. Lorrie McNeill, and many other experts. “What they're saying here is they're not doing statistical testing on adverse events. This is really insane to me,” Dr. Fraiman continued. “You know there's a problem if the vaccine group has a higher rate of them.” Dr. Joseph Fraiman, MD is an emergency physician and clinical researcher focused on harm-benefit analysis. He served as Medical Manager of Louisiana's Urban Search Rescue Disaster Task Force 1 and is lead author of a widely known re-analysis of mRNA vaccine serious harms. Follow at https://x.com/josephfraiman Dr. Stephanie Venn-Watson is Co-CEO and Co-Founder of Seraphina Therapeutics. She is a veterinary epidemiologist and author of “The Longevity Nutrient” (March 2025). Her background includes DARPA, the U.S. Navy Marine Mammal Program, and research on nutritional C15:0 deficiencies. Learn more at https://drdrew.com/fatty15 「 SUPPORT OUR SPONSORS 」 • AUGUSTA PRECIOUS METALS – Thousands of Americans are moving portions of their retirement into physical gold & silver. Learn more in this 3-minute report from our friends at Augusta Precious Metals: ⁠⁠⁠⁠https://drdrew.com/gold⁠⁠⁠⁠ or text DREW to 35052 ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠• FATTY15 – The future of essential fatty acids is here! Strengthen your cells against age-related breakdown with Fatty15. Get 15% off a 90-day Starter Kit Subscription at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://drdrew.com/fatty15⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ • PALEOVALLEY - "Paleovalley has a wide variety of extraordinary products that are both healthful and delicious,” says Dr. Drew. "I am a huge fan of this brand and know you'll love it too!” Get 15% off your first order at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://drdrew.com/paleovalley⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ • VSHREDMD – Formulated by Dr. Drew: The Science of Cellular Health + World-Class Training Programs, Premium Content, and 1-1 Training with Certified V Shred Coaches! More at https://drdrew.com/vshredmd • THE WELLNESS COMPANY - Counteract harmful spike proteins with TWC's Signature Series Spike Support Formula containing nattokinase and selenium. Learn more about TWC's supplements at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://twc.health/drew⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ 「 ABOUT THE SHOW 」 Ask Dr. Drew is produced by Kaleb Nation (⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://kalebnation.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠) and Susan Pinsky (⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://twitter.com/firstladyoflov⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠e⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠). This show is for entertainment and/or informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment. Executive Producers • Kaleb Nation - ⁠⁠⁠⁠⁠⁠⁠⁠https://kalebnation.com⁠⁠⁠⁠⁠⁠⁠⁠ • Susan Pinsky - ⁠⁠⁠⁠⁠⁠⁠⁠https://x.com/firstladyoflove⁠⁠⁠⁠⁠⁠⁠⁠ Content Producer & Booking • Emily Barsh - ⁠⁠⁠⁠⁠⁠⁠⁠https://x.com/emilytvproducer⁠⁠⁠⁠⁠⁠⁠⁠ Hosted By • Dr. Drew Pinsky - ⁠⁠⁠⁠⁠⁠⁠⁠https://x.com/drdrew⁠⁠⁠⁠⁠⁠⁠⁠ Learn more about your ad choices. Visit megaphone.fm/adchoices

In this episode, we explore a new study examining whether antidepressants and antipsychotics truly increase the risk of torsades de pointes, a potentially fatal cardiac arrhythmia. What does the evidence say about using multiple psychiatric medications together, and when should we actually be concerned? Faculty: Scott Beach, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.75 CMEs: Quick Take Vol. 75 Torsades de Pointes: Impact of Antidepressants and Antipsychotics

In this episode, we recap our break over Thanksgiving, how & what happened in the game against the Commanders, what to look forward to in Round 2 against the Raiders & we give our picks in OT!

Welcome to Dev Game Club, where this week we try something a little different. Unattached to any particular game, we chat with Ed Fries, a long-time video game developer most well-known for his work  shepherding the early days of Xbox and Microsoft Game Studios. We talk about five games of his early years that particularly affected him. Dev Game Club looks at classic video games and plays through them over several episodes, providing commentary. Podcast breakdown: 1:16:35 Break 1:16:48 Outro Issues covered: a new model for interviews, productivity software wars, a child of engineers, Lunar Lander on a calculator, 6800-based kit computer and programming in assembly, cardboard computer, jumping from BASIC to assembly language, using a print terminal, modem sounds, competitive Asteroids, the first real video game, oscilloscopes and radar, complaining to the dentist, inspiring a generation of programmers and engineers, learning by typing from magazines, the 8-bit microprocessor, getting a 6502 square root routine from Woz, using a computer terminal, an intro to Rogue and its procedural elements, a things-going-wrong simulator, "there were not that many games in the world," building a game for different player types, the D programming language and other alphabetic languages, a short remembrance of Dani Bunten Berry, Multiple Use Labor Elements, how M.U.L.E. plays, screwing your buddies, similarities to Euro strategy games, the auction phase, crystite mining, a literary game, the first original IP character in a video game, moving from real caves to fantasy, some connections, album covers from EA, expensive personal computers. Games, people, and influences mentioned or discussed: Frogger, ROMox, The Princess and the Frog, Ant Eater, Sea Chase, Tom and Ed's Bogus Software, Tom Saxton, Sucker Punch, Microsoft, Ender's Game, Phil Spencer, Xbox, Bungie, Ensemble Studios, Rare Limited, World of Warcraft, Gabe Newell, Atari 2600, Halo, 1Up Ventures Fund, Psychonauts, Keeper, Tim Schafer, Boeing, Digital Equipment Corporation, Lunar Lander, CARDIAC, Nintendo Labo, Apple ][, Atari 800, Space Wars, Asteroids, Nolan Bushnell, Ampex, Ted Dabney, Computer Space, Nutting Associates, Computer Trivia, Pong, Homeworld, Steve Wozniak, Rogue, Defeating Games for Charity, Dark Souls, HACK, PDP-11/VAX, Epyx, Walter Bright, Sid Meier, Civilization, Bruce Shelley, Age of Empires, M.U.L.E., Dani Bunten Berry, Seven Cities of Gold, Settlers of Cataan, Diplomacy, AJ Redmer, Maxis, Will Wright, Dungeon/Zork, Don Daglow, Tim Anderson, Colossal Cave Adventure/Advent, Infocom, Frank Cifaldi, Video Game History Foundation, Kate Willaert, Will Crowther, Don Woods, Mike Haas, Andrei Alexandrescu, 2001: A Space Odyssey, Populous, The Bard's Tale, Outer Wilds, Kirk Hamilton, Aaron Evers, Mark Garcia.  Next time: TBA! or more Pikmin TTDS: 40m 6s Links: Ant Eater source  Princess and Frog source Sea Chase source  Nitro source Errata: I misspoke with respect to the co-inventor of D, it was Andrei Alexandrescu. We regret the error. Twitch: timlongojr and twinsunscorp  YouTube  Discord  DevGameClub@gmail.com 

Fewer than 20% of women take part in cardiac rehabilitation (CR) programs, which is one of the most proven ways to recover and prevent another heart event Women who complete cardiac rehab lower their risk of hospitalization by up to 42% and reduce their risk of death from heart disease by as much as 58%, gaining both longer life and better quality of life Referral bias is a major reason for low participation — women are referred for cardiac rehab less often than men, and rates are even lower among Black, Hispanic, and Asian women, where participation averages just 10% to 12% Automatic referrals, flexible scheduling, home-based or hybrid options, and women-only programs are powerful, research-backed strategies that dramatically increase enrollment and completion rates Cardiac rehab isn't just exercise — it's a personalized recovery plan that rebuilds heart strength, lowers stress, and restores confidence, giving women a structured way to take back control of their health and their future

Logan Davidson joins the show to talk about the fast-moving world of Ibogaine in American and why state-based leadership is shaping the future of psychedelic reform. Davidson is the executive director of Texans for Greater Mental Health, the legislative director at VETS, and a key strategist behind Texas' landmark interest in ibogaine research. He also advises for Americans for Ibogaine. His work sits at the intersection of science, policy, and lived experience, and this conversation offers a clear look into what is happening right now. Early Themes: The Rise of State Advocacy Davidson explains how he entered politics at nineteen and how his professional path merged with psychedelic policy work during the 2021 Texas legislative session. Through that first bill, he saw how science, bipartisan cooperation, and strong local leadership could advance major reform. Early discussion focuses on: How Texas became the first state to pass a major psychedelic research bill Why ibogaine became a central focus How the special operations community helped shift political momentum The personal mental health stories that shaped Davidson's commitment This section also highlights how Americans for Ibogaine entered the conversation through veterans, researchers, and state lawmakers who felt the urgency of the opioid crisis and traumatic brain injury. Core Insights: Ibogaine, Risk, and the New Research Model In the middle portion of the episode, Davidson breaks down the strategy, challenges, and promise behind ibogaine research and state-based policy innovation. Key insights include: The unique bipartisan environment in Texas Why stories from veterans and spouses moved lawmakers The importance of medical screening for cardiac risk Why research is essential for safety How states can use funding, revenue sharing, and public health goals to shape future access What policymakers are watching right now Effectiveness for opioid use disorder Data from traumatic brain injury studies Cardiac safety protocols The risk of untreated depression and addiction The national security implications of forcing service members to seek illegal care Davidson also explains why removing the psychedelic experience from the molecule remains controversial and why many researchers believe the full experience matters. Later Discussion and Takeaways: The Road Ahead for American Ibogaine In the final part of the conversation, Davidson speaks about the future of American Ibogaine and the broader psychedelic field. He outlines why local leadership matters, why federal funding, like what Psychedelic Medicine Coalition is supporting, could be the next major tipping point, and how big pharmaceutical companies may eventually enter the space through acquisitions or proprietary molecule development. Concrete takeaways include: States should expect clear benefits: lower-cost treatments, shared revenue, and local control Community leaders, not outsiders, often drive legislative wins The need for long-term safety data remains National security concerns highlight why regulated access must expand Federal research money could radically transform the pace and scale of studies He also encourages listeners to join or build local organizations, since nearly every major win comes from people who live in the state pushing from the ground up. Frequently Asked Questions Is Ibogaine safe? Ibogaine has cardiac risks that require medical screening and careful monitoring. Researchers stress that safety improves with proper protocols and more clinical data. Why is Ibogaine important for veterans? Many special operations veterans report major benefits for traumatic brain injury, PTSD, and addiction. Their stories have driven political momentum. How are states involved in Ibogaine research? States like Texas are funding clinical trials, drug development, shaping policy, and exploring revenue and access models to support long-term public health benefits. Will Ibogaine become federally supported in America? New federal interest, including major grants and bipartisan discussions, suggests that broader support may be coming in the next few years. Closing Thoughts This episode shows why the work of Logan Davidson sits at the center of today's psychedelic resurgence. It highlights a complex but hopeful moment where science, policy, and lived experience are beginning to align. As American Ibogaine research expands, state leaders, clinicians, veterans, and advocates all have a role in shaping a safer and more effective future for these treatments.

Commentary by Dr.  Martin Bergmann.

12/1/2025 | Cardiac

12/1/2025 | Cardiac

Enlace del curso: https://app.behindtheknife.org/premium/repaso-para-el-examen-de-certificaci-n-en-cirug-a-general Behind the Knife es el podcast quirúrgico líder en el mundo y una plataforma de educación quirúrgica. Nuestra misión es crear contenido innovador de educación quirúrgica que sea accesible para todos. Estamos muy emocionados de expandirnos al público hispanohablante y ofrecerles 4 episodios de muestra de nuestro Curso de Repaso para el examen de certificación de Cirugía General. Hoy, escucharás un caso de muestra de este curso de repaso en audio, que incluye 100 escenarios. El curso tiene un formato emocionante y completamente único. Cada uno de los 100 caso consta de dos partes. La primera parte es un caso oral perfectamente ejecutado que imita la realidad. Cada caso tiene una duración de cinco a siete minutos e incluye una variedad de tácticas y estilos. Si logras alcanzar este nivel de desempeño en tu preparación, seguramente aprobarás el examen de certificación con éxito. La segunda parte introduce comentarios de alto rendimiento para cada escenario. Estos comentarios incluyen consejos y trucos para ayudarte a dominar los escenarios más desafiantes, además de una enseñanza práctica y fácil de entender que cubre los temas más confusos que enfrentamos como cirujanos generales. Estamos seguros de que encontrarás este enfoque único de doble formato como una forma altamente efectiva de prepararte para el examen. Nuestro contenido está disponible en nuestras aplicaciones para iOS y Android y en nuestro sitio web (behindtheknife.org). Por favor, consulta las notas del programa para más información. Nos encantaría escuchar tus comentarios sobre este episodio enviando un correo electrónico a hello@behindtheknife.org y apreciamos tu ayuda para difundir la palabra entre tus colegas si disfrutas del material. Este contenido incluye 97 descripciones operatorias para todos los procedimientos comunes —y la mayoría de los poco comunes— incluidos en el Currículo de Cirugía General SCORE. Cada descripción está diseñada para ayudar a los candidatos a prepararse de manera eficaz para el Examen de Certificación en Cirugía General. presentadores de podcast: - Auri P. Garcia Gonzalez, MD PhD nació en San Juan, Puerto Rico, y se trasladó a los Estados Unidos en el 2012 para sus estudios graduados. Actualmente, es estudiante de post-grado en cirugía general en Duke University. - Diego Schaps, MD, MPH es un residente de cirugía general en Duke y nació en Miami, en el estado de la Florida. Sus padres nacieron en El Salvador. Disclaimer: Los productos de contenido de Behind the Knife son únicamente para fines educativos. No diagnosticamos, tratamos ni ofrecemos consejos específicos para pacientes. ------ Behind the Knife is the world's leading surgical podcast and surgical education platform.  Our mission is to create innovative surgical education content that is accessible to all.  We are very excited to expand into the spanish audience and bring you 4 sample episodes of our General Surgery Oral Board Review Course which will be released over the course of the next week. Today, you'll hear a sample scenario from this comprehensive audio review course which includes 100 scenarios.  The course has an exciting and entirely unique format. Each of the 100 scenarios includes two parts. The first part is a perfectly executed oral board scenario that mimics the real thing. Scenarios are five to seven minutes long and include a variety of tactics and styles. If you're able to achieve this level of performance in your preparation, you are sure to pass the oral exam with flying colors. The second part introduces high yield commentary to each scenario. This commentary includes tips and tricks to help you dominate the most challenging scenarios in addition to practical, easy to understand teaching that covers the most confusing topics that we face as general surgeons. We are confident you will find this unique dual format approach a highly effective way to prepare for the test. The course contains crisp, concise operative descriptions that cover all SCORE common topics and and most SCORE uncommon topics. Our content is available on our iOS and Android apps and website (behindtheknife.org).  Please check the show notes for more information. We would love to hear your feedback by emailing hello@behindtheknife.org and appreciate your help spreading the word to your colleagues if you enjoy the material. Hosts: - Auri P. Garcia Gonzalez, MD PhD was born and raised in San Juan, Puerto Rico and moved to the US in 2012 for graduate studies. At present, she is a surgical resident at Duke University. - Diego Schaps, MD, MPH is a general surgery resident at Duke and was born in Miami, Florida. His parents were born in El Salvador. Please visit https://behindtheknife.org to access other high-yield surgical education podcasts, videos and more. If you liked this episode, check out our recent episodes here: https://app.behindtheknife.org/listen

Send us a textA chaotic overtime win over Arizona shows both sides of this team: careless turnovers and ice-cold clutch throws. We weigh late-game analytics, celebrate a key return on offense, and map the most interesting playoff path Jacksonville has seen in years.• Wildcard position improving with many winnable games ahead• Trevor Lawrence volatility and late-game efficiency• Breakdown of Lawrence's picks and the coverage adjustments he saw• Brenton Strange's return opening the middle of the field• Parker Washington's chemistry and special teams impact• Defensive pressure spike, DB blitzes, and front improvements• Coaching aggression on fourth down and clock nuances• AFC playoff matchups to target and avoid• Titans preview and trap-game risk managementUse the promo code Touchdown Jaguars on SeatGeek to save $20 on your first eligible SeatGeek purchaseDon't forget to like, share, and give the podcast five stars on your podcast playerTouchdown Jaguars Linktree James Johnson and Phil Barrera bring you the best and most up to date Jacksonville Jaguars news. "Touchdown Jaguars!" is a tribute to the prospective ownership group "Touchdown Jacksonville!" In 1991, the NFL announced plans to add two expansion teams and "Touchdown Jacksonville!" announced its bid for a team, and Jacksonville was ultimately chosen as one of five finalists. In November 1993, the NFL owners voted 26–2 in favor of awarding the 30th franchise to Jacksonville. James and Phil have been fans of the franchise ever since and have had the honor (and sometimes dishonor) of covering the team professionally since 2017. The rest as they say, is history.

“Can you really be thankful when your heart is breaking?”In this powerful Thanksgiving episode of Female Voices: Life & Loss, Teresa and LaWayna open up about navigating grief during the holidays and how gratitude can coexist with pain. From personal stories of loss to a helicopter ride filled with fear and prayer, they share authentic perspectives on reframing, community, and starting small gratitude practices that help bring calm to an overwhelmed mind.Whether you're grieving someone you love, struggling financially, or just feeling disconnected heading into the holidays—this conversation will remind you that you're not alone, and you can hold grief and grace at the same time.Quotes worth remembering● “You can absolutely have gratitude and be grieving at the same time—we are complicated human beings.” – LaWayna ● “Sometimes instead of asking ‘What am I grateful for?' ask ‘What do I have?'” – Teresa● “When we slow down and breathe, even for two minutes, the body begins to restore.” – Teresa● “I told the Lord, help your little sad child today.” – LaWayna ● “Maybe start with the ungrateful list before the grateful one.” – LaWayna Topics Covered● Navigating grief during the holiday season● How gratitude affects our brain chemistry and cortisol levels● Different gratitude practices (journaling, prayer, spoken word, connection)● The power of community in healing (AA, friendships, families)● Reframing and slowing down to be present● Adventuring outside comfort zones as an act of livingKey Takeaways● You can hold both grief and gratitude at the same time. Healing doesn't require pretending you're okay.● Starting small helps: Even a 2-minute breathing or gratitude moment can help reduce stress.● There is no one right way to practice gratitude. Journaling, prayer, speaking, community—find what works for you.● Reframing can shift mental state. Sometimes “What do I have?” is easier than “What am I grateful for?”● Getting emotions out (even the negative ones) may help. Try writing an “ungrateful list” before moving into gratitude. Suggested Timestamps00:00 – Welcome & Thanksgiving intro02:13 – Acknowledging current struggles (financial, loss, food scarcity)05:04 – Josh's gratitude practice through AA community07:02 – Holding grief and gratitude together11:19 – Scientific impact of gratitude (dopamine, serotonin)14:25 – How grief floods the body with cortisol17:07 – Breathing practice and beginning with 2 minutes22:49 – Helicopter moment: prayer, fear, and reframing27:30 – “What do I have?” as a gratitude entry point28:00 – Ungrateful list exercise29:18 – Tool announcement for listeners30:21 – Thanksgiving photos & family traditions32:21 – Closing remarks & listener engagementMentions & Shoutouts● AA Support Group – demonstrating accountability and morning gratitude list.Episode Extras●

Joined on this episode by two awesome guests. One of my favorite people on the planet in Chief Frank Leeb, and the other one that I am excited to meet and have an awesome conversation with in Kory Pearn.  We plan to talk about all the issues that can blindside us in the fire-service. The mission of Crackyl magazine.  Cancer, Cardiac, Physical fitness. How can we ensure that a young firefighter becomes an old firefighter! an informative conversation and as always the best laid plans of me and my guests was beautifully derailed by the awesome question from the Scrap audience.  

Dystrophinopathies are heritable muscle disorders caused by pathogenic variants in the DMD gene, leading to progressive muscle breakdown, proximal weakness, cardiomyopathy, and respiratory failure. Diagnosis and management are evolving areas of neuromuscular neurology. In this episode, Kait Nevel, MD, speaks with Divya Jayaraman, MD, PhD, an author of the article "Dystrophinopathies" in the Continuum® October 2025 Muscle and Neuromuscular Junction Disorders issue. Dr. Nevel is a Continuum® Audio interviewer and a neurologist and neuro-oncologist at Indiana University School of Medicine in Indianapolis, Indiana. Dr. Jayaraman is an assistant professor of neurology and pediatrics in the division of child neurology at the Columbia University Irving Medical Center in New York, New York. Additional Resources Read the article: Dystrophinopathies Subscribe to Continuum®: shop.lww.com/Continuum Earn CME (available only to AAN members): continpub.com/AudioCME Continuum® Aloud (verbatim audio-book style recordings of articles available only to Continuum® subscribers): continpub.com/Aloud More about the American Academy of Neurology: aan.com Social Media facebook.com/continuumcme @ContinuumAAN Host: @IUneurodocmom Full episode transcript available here Dr Jones: This is Dr Lyell Jones, Editor-in-Chief of Continuum. Thank you for listening to Continuum Audio. Be sure to visit the links in the episode notes for information about earning CME subscribing to the journal, and exclusive access to interviews not featured on the podcast. Dr Nevel: Hello, this is Dr Kate Nevel. Today I'm interviewing Dr Divya Jayaraman about her article on dystrophinopathies, which she wrote with Dr Partha Ghosh. This article appears in the October 2025 Continuum issue on muscle and neuromuscular junction disorders. Divya, welcome to the podcast, and please introduce yourself to the audience. Dr Jayaraman: Thank you so much, Dr Nevel. My name is Divya, and I am an assistant professor of Neurology and Pediatrics at Columbia University Irving Medical Center, and also an attending physician in the Pediatric Neuromuscular program there. In that capacity, I see patients with pediatric neuromuscular disorders and also some general pediatric neurology patients and also do research, primarily clinical research and clinical trials on pediatric neuromuscular disorders. Dr Nevel: Wonderful. Thank you for sharing that background with us. To set us on the same page for our discussion, before we get into some more details of the article, perhaps, could you start with some definitions? What comprises the dystrophinopathies? What are some of the core features? Dr Jayaraman: So, the dystrophinopathies, I like that term because it is a smaller subset from the muscular dystrophies. The dystrophinopathies are a spectrum of clinical phenotypes that are all associated with mutations in the DMD gene on chromosome X. So, that includes DMD---or, Duchenne muscular dystrophy---, Becker muscular dystrophy, intermediate muscular dystrophy (which falls in between the two), dilated cardiomyopathy, asymptomatic hyperCKemia, and manifesting female carriers. In terms of the core features of these conditions, so, there's some variability, weakness being prominent in Duchenne and also Becker. The asymptomatic hyperCKemia, on the other hand, may have minimal symptoms and might be found incidentally by just having a high CK on their labs. They all will have some degree of elevated CK. The dilated cardiomyopathy patients, and also the Becker patients to a lesser degree, will have cardiac involvement out of proportion to skeletal muscle involvement, and then the manifesting carriers likewise can have elevated CK and prominent cardiac involvement as well as some milder weakness. Dr Nevel: Now that we have some definitions, for the practicing neurologists out there, what do you think is the most important takeaway from your article about the dystrophinopathies? Dr Jayaraman: I like this question because it suggests that there's something that, really, any neurologist could do to help us pick up these patients sooner. And the big takeaway I want everyone to get from this is to check the CK, or creatine kinase, level. It's a simple, cheap, easy test that anyone can order, and it really helps us a lot in terms of setting the patient on the diagnostic odyssey. And in terms of whom you should be thinking about checking a CK in, obviously patients who present with some of the classic clinical features of Duchenne muscular dystrophy. This would include young boys who have toe walking, as they're presenting, sign; or motor delayed, delayed walking. They may have calf hypertrophy, which is what we say nowadays. You might have seen calf pseudohypertrophy in your neurology textbooks, but we just say calf hypertrophy now. Or patients can often have a Gowers sign or Gowers maneuver, which is named after a person called Gowers who described this phenomenon where the child will basically turn over and use their hands on the floor to stand up, usually with a wide-based gait, and then they'll sort of march their hands up their legs. That's the sort of classic Gowers maneuver. There are modified versions of that as well. So, if anyone presents with this classic presentation, for sure the best first step is to check a CK. But I would also think about checking a CK for some atypical cases. For example, any boy with any kind of motor or speech delay for whom you might not necessarily be thinking about a muscle disorder, it's always good practice to check a CK. Even a boy with autism for whom you may not get a good clinical exam. This patient might present to a general pediatric neurology clinic. I always check a CK in those patients, and you'll pick up a lot of cases that way. For the adult folks in particular, the adult neurologist, a female patient could show up in your clinic with asymptomatic hyperCKemia. And I think it's an important differential to think about for them because this could have implications not just for their own cardiac risks, but also for their family planning. Dr Nevel: So, tell us a little bit more about the timing of diagnosis. Biggest takeaway: check a CK if this is anywhere on your radar, even if somewhat of an atypical case. Why is it so important to get kiddos started on that diagnostic odyssey, as you called it, early? Dr Jayaraman: This is especially important for kids because if they especially get a Duchenne muscular dystrophy diagnosis, you might be making them eligible for treatments that we've had for some time, and also treatments that were not available earlier that hinge on making that diagnosis. So, for example, people may be skeptical about steroids, but there's population data to suggest that initiation and implementation of steroids could delay the onset of loss of ambulation as much as three years. So, you don't want to deprive patients of the chance to get that. And then all the newer emerging therapies---which we'll be talking about later, I'm sure---require a Duchenne muscular dystrophy diagnosis. So, that's why it's so important to check a CK, have this on your radar, and then get them to a good specialist. Dr Nevel: I know that you alluded already, or shared a few of the kind of exam paroles or findings among patients with dystrophinopathy. But could you share with us a little bit more how you approach these patients in the clinic who are presenting with muscle weakness, perhaps? And how do you approach this or think about this in terms of ways to potentially differentiate between a dystrophinopathy versus another cause of motor weakness or delay? Dr Jayaraman: It's helpful to think through the neuraxis and what kinds of disorders can present along that neuraxis. A major differential that I'm always thinking about when I'm seeing a child with proximal weakness is spinal muscular atrophy, which is a genetic anterior horn cell disorder that can also present in this age group. And some of the key differences there would be things like reflexes. So, you should have dropped reflexes in spinal muscular atrophy. In DMD, surprisingly, they might have preserved Achilles reflexes even if their patellar reflexes are lost. It may only be much later that they go on to lose their Achilles reflex. So, if you can get an Achilles reflex, that's quite reassuring, and if you cannot, then you need to be thinking about spinal muscular atrophy. They can both have low muscle tone and can present quite similarly, including with proximal weakness, and can even have neck flexion weakness. So, this is an important distinction to make. The reason for that is, obviously there are treatments for both conditions, but for spinal muscular atrophy, timing is very, very important. Time is motor neurons, so the sooner you make that diagnosis the better. Other considerations would be the congenital muscular dystrophies. So, for those that they tend to present a lot younger, like in infancy or very early on, and they can have much, much higher CKS in that age range than a comparable Duchenne or Becker muscular dystrophy patient. They can also have other involvement of the central nervous system that you wouldn't see in the dystrophinopathies, for example. My mnemonic for the congenital muscular dystrophies is muscle-eye-brain disease, which is one of the subtypes. So, you think about muscle involvement, eye involvement, and brain involvement. So, they need an ophthalmology valve. They can have brain malformations, which you typically don't see in the dystrophinopathies. I think those are some of the major considerations that I have. Obviously, it's always good to think about the rest of the neuraxis as well. Like, could this be a central nervous system process? Do they have upper motor neuron signs? But that's just using all of your exam tools as a neurologist. Dr Nevel: Yeah, absolutely. So, let's say you have a patient in clinic and you suspect they may have a dystrophinopathy. What is your next diagnostic step after your exam? Maybe you have an elevated CK and you've met with the patient. What comes next? Dr Jayaraman: Great question. So, after the CK, my next step is to go to genetics. And this is a bit of a change in practice over time. In the past we would go from the CK to the muscle biopsy before genetic testing was standard. And I think now, especially in kids, we want to try and spare them invasive procedures where possible. So, genetic testing would be the next step. There are a few no-charge, sponsored testing programs for the dystrophinopathies and also for some of the differential diagnosis that I mentioned. And I think we'll be including links to websites for all of these in the final version of the published article. So, those are a good starting point for a genetic workup. It's really important to know that, you know, deletions and duplications are a very common type of mutation in the DMD gene. And so, if you just do a very broad testing, like whole exome, you might miss some of those duplications and deletions. And it's important to include both checking for duplications and deletions, and also making sure that the DMD gene is sequenced. So always look at whatever genetic test you're ordering and making sure that it's actually going to do what you want it to do. After genetics, I think that the sort of natural question is, what if things are not clear after the genetics for some reason? We still use biopsy in this day and age, but we save it for those cases where it's not entirely clear or maybe the phenotype is a little bit discordant from the genotype. So, for mutations that disrupt the reading frame, those tend to cause Duchenne muscular dystrophy, whereas mutations that preserve the reading frame tend to cause Becker muscular dystrophy. There are some important exceptions to this, which is where muscle biopsy can be especially helpful in sorting it out. So, for example, there are some early mutations early in the DMD gene where, basically, they find an alternate start codon or an initiation codon to continue with transcription and translation. So, you end up forming a largely functional, somewhat truncated protein that gives you more of a milder Becker phenotype. On the other hand, you can have some non-frameshift or inframe mutations that preserve the reading frame, but because they disrupt a very key domain in the protein that's really crucial for its function, you can actually end up with a much more severe Duchennelike phenotype. So, for these sorts of cases, you might know a priori you're dealing with them, but might just be a child who is who you think has DMD has a mutation that's showed up on testing. There isn't enough in the literature to point you one way or another, but they look maybe a little milder than you would expect. That would be a good kid to do a biopsy in because there are treatment decisions that hinge on this. There are treatments that are only for Duchenne that someone with a milder phenotype would not be eligible for. Dr Nevel: So, that kind of stepwise approach, but maybe not all kids need a muscle biopsy is what I'm hearing from you. If it's a mutation that's been well-described in the literature to be fitting with Duchenne, for example. Dr Jayaraman: Absolutely. Dr Nevel: So, after you confirm the diagnosis through genetic testing---and let's say, you know, whether or not you do a muscle biopsy or not, after you know the diagnosis is a dystrophinopathy---how do you counsel the families and your patients? What are the most important points to relay to families, especially in that initial phase where the diagnosis is being made? Dr Jayaraman: This is a lot of what we do in pediatric neurology in general, right? So, I actually picked up this approach from the pediatric hematology oncology specialists at Boston Children's. They had this concept of a day-zero conversation, which is the day that you disclose the life-changing diagnosis or potentially, at some point, terminal diagnosis to a family. And some of the key components of that are a not beating around the bush, telling them what the diagnosis is, and then letting them have whatever emotional response they're going to have in the moment. And you may not get much further than that, but honestly, you want them to take away, this is what my child has. I did not do anything to cause this, nor could I have done anything to prevent this. Because often for these genetic conditions, there's a lot of guilt, a lot of parental guilt. So, you want to try and assuage that as much as possible. And then to know that they're not going to be alone on this journey; that, you know, they don't have to have it all figured out right then, but we can always come back and answer any questions they have. There's going to be a whole team of specialists. We're going to help the family and the kid manage this condition. Those are sort of my big takeaways that I want them to get. Dr Nevel: Right. And that segues into my next question, which is, who is part of that team? I know that these teams that help take care of people with dystrophinopathies and other muscle disorders can be very large teams that span multiple specialists. Can you talk a little bit more about that for this group of patients? Dr Jayaraman: Of course. So, the neuromuscular neurologist, really, our role is in coordinating the diagnosis, the initiation of any disease-specific treatments, and coordinating care with a whole group of specialists. So, we're sort of at the center of that, but everyone else is equally important. So, the other specialists include physical therapists; occupational therapists; rehab doctors or physiatrists; orthotists who help with all of the many braces and other devices that they might need, wheelchairs; pulmonology, of course, for managing the respiratory manifestations of this. It becomes increasingly important over time, and they are involved early on to help monitor for impending respiratory problems. Cardiac manifestations, this is huge and something that you should be thinking about even for your female carriers, the mother of the patient you're seeing in the clinic, or your patient who comes to adult clinic with asymptomatic hyperCKemia. if you end up making a diagnosis of DMD carrier for those patients, or if you make a Becker diagnosis, the cardiac surveillance is even more important because the cardiac involvement can be out of proportion to the skeletal muscle weakness. And of course, extremely important for the Duchenne patients as well. Endocrinologists are hugely important because in the course of treating patients with steroids, we end up giving them a lot of iatrogenic endocrinologic complications. Like they might have delayed puberty, they might have loss of growth, of height; and of course metabolic syndrome. So, endocrinology is hugely important. They're also important in managing things like fracture prevention, osteoporosis, prescribing bisphosphonates if necessary. Nutrition and GI are also important, not just later on when they might need assistance to take in nutrition, whether that's through tube feeds, but also earlier on when we're trying to manage the weight. Orthopedics, of course, for the various orthopedic complications that patients develop. And then finally, a word must be said for social work and behavioral and mental health specialists, because a lot of this patient population has a lot of mental health challenges as well. Dr Nevel: After you give the diagnosis, you've counseled the patient and families and you've had those kind of initial phase discussions, the day-zero discussion, when you start getting into discussions or thoughts about management, disease-specific medication. But what are the main categories of the treatment options, and maybe how do you kind of approach deciding between treatment options for your patients? Dr Jayaraman: So, there are two broad categories that I like to think about. So, one is the oral corticosteroids and oral histone deacetylase, or HDAC inhibitors, which share the common characteristic that they are non-mutation specific. And within corticosteroids, patients now have a choice between just Prednisone or Prednisolone, or Deflazacort or Vermilion. The oral HDAC inhibitors are newly FDA-approved as a nonsteroidal therapy in addition to corticosteroids in DMD patients above six years of age. I would say we're in the early phase of adoption of this in clinical practice. And then the other big category of treatment options would be the genetic therapies as a broad bucket, and this would include gene therapy or gene replacement therapy, of which the most famous is the microdystrophin gene therapy that was FDA-approved first on an accelerated approval basis for ages four to eight, and then a full approval in that age group as well as an accelerated approval for all comers, essentially, with DMD. This is obviously controversial. Different centers approach this a bit differently. I think our practice at our site has been to focus on the ambulatory population, just thinking about risk versus benefit, because the risks are not insignificant. So really this is something that should be done by experienced sites that have the bandwidth and the wherewithal to counsel patients through all of this and to manage complications as they arise with regular monitoring. And then another class that falls within this broader category would be the Exon-skipping therapies. So as the name suggests, they are oligonucleotides that cause an Exon to be skipped. The idea is, if there is a mutation in a particular Exon that causes a frame shift, and there's an adjacent Exon that you can force skipping of, then the resulting protein, when you splice the two ends together, will actually allow restoration of the reading frame. I think the picture I want to paint is that there's a wide range of options that we present to families, not all of which everyone will be eligible for. And they all have different risk profiles. And I really think the choice of a particular therapy has to be a risk-benefit decision and a shared decision-making process between the physician and the family. Dr Nevel: What is going on in research in this area? And what do you think will be the next big breakthrough? I know before we started the recording you had mentioned that there's a lot of things going on that are exciting. And so, I'm looking forward to hearing more. Dr Jayaraman: Of course. So, I'll be as quick as I can with this. But I mentioned that next-generation Exon skipping therapies, I think the hope is that they will be better at delivering the Exon skipping to the target tissue and cells and that they might be more efficacious. I'm also excited about next-generation gene therapies that might target muscle more specifically and hopefully reduce the off-target effects, or combination use of gene therapies with other immunosuppressive regimens to improve the safety profile and maybe someday allow redosing, which we cannot do currently. Or potentially targeting the satellite cells, which are the muscle stem cells, again, to improve the long term durability of these genetic therapies. Dr Nevel: That's great, thank you for sharing. Thank you so much for talking to me today about your article. I really enjoyed learning more about the dystrophinopathies. Today I've been interviewing Dr Divya Jayaraman about her article on the dystrophinopathies, which she wrote with Dr Partha Ghosh. This article appears in the October 2025 Continuum issue on muscle and neuromuscular junction disorders. Please be sure to check out the Continuum Audio episodes from this and other issues. Also, please read the Continuum articles for more details than what we were able to get to today during our discussion. Thank you, as always, so much to the listeners for joining us today, and thank you, Divya, for sharing all of your knowledge with us today. Dr Jayaraman: Thank you so much for having me on the podcast. Dr Monteith: This is Dr Teshamae Monteith, Associate Editor of Continuum Audio. If you've enjoyed this episode, you'll love the journal, which is full of in-depth and clinically relevant information important for neurology practitioners. Use the link in the episode notes to learn more and subscribe. AAN members, you can get CME for listening to this interview by completing the evaluation at continpub.com/audioCME. Thank you for listening to Continuum Audio.

We talk with physiologist Elliot Jenkins about how passive heat acclimation boosts VO2 max, hemoglobin mass, and cardiac function in trained runners without adding mechanical training load. Practical protocols, safety tips, and open research questions round out a clear, actionable guide to using heat wisely.• Elliot's path from Otago to a PhD in the UK• Why passive heat instead of exercising in heat• Hematology: plasma volume expansion • Cardiac changes: larger end-diastolic volume and stroke volume• VO2 max and speed gains in trained runners• Practical protocol: time, temperature, frequency, hydration• Safety: dizziness, slow exits, supervision, low blood pressure• Dose-response unknowns and hot-climate athletes• Heat vs cold and contrast for recovery and adaptation• Where to find Elliot's paper and social links (see below).Follow Elliott Jenkins on X @E_J_Jenkins His paper is published here: https://physoc.onlinelibrary.wiley.com/doi/10.1113/JP289874

A story of calm confidence, healing, and letting go of perfection. Episode #233 What happens when you stop chasing perfection and start trusting your body? In this heartfelt conversation, Audrey shares with Coach Lisa how she moved from fear and confusion to calm confidence by embracing nourishment, community, and self-compassion. Audrey's journey reminds us that fasting isn't just about hours — it's about listening to your body, releasing perfectionism, and keeping "a hand on the wagon," even when life gets messy. What you'll learn: Why fasting alone wasn't enough for Audrey The mindset shift that helped her release perfectionism How she advocated for herself through confusing medical advice The practices that improved her sleep, confidence, and cardiac markers How she navigates social eating, travel, and cravings with ease Books mentioned in this episode: The Paleo Cure — Chris Kresser Adrenal Transformation Protocol — Izabella Wentz Fast Like a Girl — Dr. Mindy Pelz   The transcript for this episode is available on our website:

On this episode of the Donut of Destiny, hosts Sotirios Evangelou, MD, FSCCT and Nisha Hosadurg , MBBS speak with guest Alan Vainrib, MD on how computational fluid dynamics (CFD) is emerging as a powerful research tool for understanding blood-flow behavior in structural heart disease. Using CT/MRI-based models, CFD can simulate pressures, velocities, shear stress and even post-procedure hemodynamics — offering new possibilities for evaluating aortic stenosis, planning TAVR and guiding mitral, tricuspid and LAAO interventions.

On today's show: At what temperature do you stop wearing shorts? 02:31 – Detroit Lions narrowly defeat Giants, and the season is on the line The "Cardiac Cats" deliver another stressful win: the Lions barely get by the Giants. Jer and Fletcher break down the wild ride that is the Jameis Winston experience ("more fun when it's not your team on the line!"), and how Jamir Gibbs stepped up in historic fashion. Deep dive into what's working and what isn't—especially a candid convo about Jared Goff, the offensive coordinator, and whether the Lions are too predictable. The hosts highlight what must improve for Detroit with national eyes on them for Thanksgiving against the Packers—a critical NFC North matchup. Both agree: If the Lions want a real shot at the playoffs, they basically need to win out.  11:12 – Detroit Pistons: 12-Game Win Streak and Rising Hopes The Pistons are HOT: 14-2 with a 12-game win streak, taking down Milwaukee on the road (even if Giannis was out). "Are the Pistons for real?" Discussion weighs schedule quality, team growth, the impact of new players, and how Detroit is earning national respect. Local pride watch: Shoutout to Ryan Rollins (Macomb Dakota) leading Milwaukee in the absence of their stars. Being able to expect the Pistons to win games, not just "play hard"—Detroit fans everywhere can relate how good this feels! Call to listeners for vintage Pistons gear for the studio. 18:11 – Red Wings: "Wings in Flight" and Atlantic Division Leaders Quick coverage of the Red Wings' strong season—they're leading the Atlantic and scoring with flash. Props to Dylan Larkin, DeBrincat, and Lucas Raymond, plus some talk about the Yzerplan paying off. 19:35 – Stephen Carroll retires as DCFC Captain for Front Office Role Longtime Detroit City FC captain Stephen Carroll announces retirement from the pitch but stays with the club in a (yet-to-be-named) front office role. Feedback as always - dailydetroit -at- gmail -dot- com or leave a voicemail 313-789-3211. Follow Daily Detroit on Apple Podcasts: https://podcasts.apple.com/us/podcast/daily-detroit/id1220563942 Or sign up for our newsletter: https://www.dailydetroit.com/newsletter/ Support us on Patreon: https://www.patreon.com/DailyDetroit    

Laurence & Spiegs react to another crazy Bulls victory last night a 122-121 win over Portland.

CardioNerds (Dr. Kelly Arps, Dr. Naima Maqsood, and Dr. Elizabeth Davis) discuss chronic AF management with Dr. Edmond Cronin. This episode seeks to explore the chronic management of atrial fibrillation (AF) as described by the 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. The discussion covers the different AF classifications, symptomatology, and management including medications and invasive therapies. Importantly, the episode explores current gaps in knowledge and where there is indecision regarding proper treatment course, as in those with heart failure and AF. Our expert, Dr. Cronin, helps elucidate these gaps and apply guideline knowledge to patient scenarios. Audio editing for this episode was performed by CardioNerds intern Dr. Bhavya Shah. CardioNerds Atrial Fibrillation PageCardioNerds Episode PageCardioNerds AcademyCardionerds Healy Honor Roll CardioNerds Journal ClubSubscribe to The Heartbeat Newsletter!Check out CardioNerds SWAG!Become a CardioNerds Patron! Pearls Review the guidelines- Catheter ablation is a Class I recommendation for select patient groups  Appropriately recognize AF stages- preAF conditions, symptomatology, classification system (paroxysmal, persistent, long-standing persistent, permanent)  Be familiar with the EAST-AFNET4 trial, as it changed the approach of rate vs rhythm control  Understand treatment approaches- lifestyle modifications, management of comorbidities, rate vs rhythm control medications, cardioversion, ablation, pulmonary vein isolation, surgical MAZE  Sympathize with patients- understand their treatment goals  Notes Notes: Notes drafted by Dr. Davis.    What are the stages of atrial fibrillation?   The stages of AF were redefined in the 2023 guidelines to better recognize AF as a progressive disease that requires different strategies at the different therapies  Stage 1 At Risk for AF: presence of modifiable (obesity, lack of fitness, HTN, sleep apnea, alcohol, diabetes) and nonmodifiable (genetics, male sex, age) risk factors associated with AF  Stage 2 Pre-AF: presence of structural (atrial enlargement) or electrical (frequent atrial ectopy, short bursts of atrial tachycardia, atrial flutter) findings further pre-disposing a patient to AF  Stage 3 AF: patient may transition between these stages  Paroxysmal AF (3A): intermittent and terminates within ≤ 7 days of onset  Persistent AF (3B): continuous and sustained for > 7 days and requires intervention  Long-standing persistent AF (3C): continuous for > 12 months   Successful AF ablation (3D): freedom from AF after percutaneous or surgical intervention  Stage 4 Permanent AF: no further attempts at rhythm control after discussion between patient and clinician   The term chronic AF is considered obsolete and such terminology should be abandoned   What are common symptoms of AF?   Symptoms vary with ventricular rate, functional status, duration, and patient perception  May present as an embolic complication or heart failure exacerbation  Most commonly patients report palpitations, chest pain, dyspnea, fatigue, or lightheadedness. Vague exertional intolerance is common  Some patients also have polyuria due to increased production of atrial natriuretic peptide  Less commonly can present as tachycardia-associated cardiomyopathy or syncope  Cardioversion into sinus rhythm may be diagnostic to help determine if a given set of symptoms are from atrial fibrillation to help guide the expected utility of more aggressive rhythm control strategies.   What are the current guidelines regarding rhythm control and available options?  COR-LOE 1B: In patients with reduced LV function and persistent (or high burden) AF, a trial of rhythm control should be recommended to evaluate whether AF is contributing to the reduced LV function   COR-LOE 2a-B: In patients with reduced LV function and persistent (or high burden) AF, a trial of rhythm control should be recommended to evaluate whether AF is contributing to the reduced LV function. In patients with a recent diagnosis of AF (

Thursday Hour 1: Is Sean a movie snob? Tommy Birch & the Cardiac Bulls

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/UBF865. CME/NCPD/CPE/AAPA/IPCE credit will be available until November 28, 2026.Exploring New Paradigms in Transthyretin Cardiac Amyloidosis Care: Experts vs AI In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Alnylam Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/UBF865. CME/NCPD/CPE/AAPA/IPCE credit will be available until November 28, 2026.Exploring New Paradigms in Transthyretin Cardiac Amyloidosis Care: Experts vs AI In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Alnylam Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/UBF865. CME/NCPD/CPE/AAPA/IPCE credit will be available until November 28, 2026.Exploring New Paradigms in Transthyretin Cardiac Amyloidosis Care: Experts vs AI In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Alnylam Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/UBF865. CME/NCPD/CPE/AAPA/IPCE credit will be available until November 28, 2026.Exploring New Paradigms in Transthyretin Cardiac Amyloidosis Care: Experts vs AI In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Alnylam Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

Become a member of The Real Science of Sport Supporters Club to show your support and have your say. A perk of membership is Discourse, our community that chats about training, sports science, physiology and news.Show notesA midweek whip around the world of sport, with some sports science and management insights on stories making headlines this week. We cover:The LA 2028 Olympic Track and Field programme was announced last week. It features three 100m races on one day for the women, and no option for a 400m/400m hurdle double, are among the surprises. We discuss the effects on athletes and the missed opportunitiesTriathlon's T100 series was plunged into chaos with miscounted laps, result changing decisions, and even a vote on whether rules were applied to the satisfaction of athletes. We discuss the fiasco in DubaiBoxing continues its (d)evolution to WWE, with a fight announced between Anthony Joshua and Jake Paul. A gimmick, for sure. Too dangerous? We discussWorld Rugby announced a new calendar for 2026, aimed at giving more relevance and meaning to Tour matches. The schedule has pros and cons, creating a travel load for teams that will require some accommodation for player welfareAnd finally, cardiac events among spectators at last week's ATP Finals are the trigger for a short discussion about the risks of WATCHING sport, with some interesting studies showing how risk increases when people are invested in the resultOther linksThe paper studying cardiac arrests at Gillette StadiumThe cardiac event risk is slightly higher in football in the NetherlandsLosing, but not winning, a Superbowl increases the risk of cardiovascular death Hosted on Acast. See acast.com/privacy for more information.

In this episode Sandy Vance sits down with Dr. Kenneth Stein, Senior Vice President and Global Chief Medical Officer at Boston Scientific, to explore how artificial intelligence is revolutionizing cardiology from diagnosis to treatment.Dr. Stein shares how Boston Scientific is tackling one of healthcare's biggest challenges: too much data and too little insight. From AI-driven heart monitors that detect dangerous rhythms before doctors can see them, to tools that democratize expert-level cardiac imaging, to predictive algorithms that warn clinicians of heart failure weeks before hospitalization. Tune in to hear how AI is not replacing doctors but empowering them, why clinical rigor still matters in the age of algorithms, and what it means for the future of cardiology.In this episode, they talk about:What it means to have too much dataThree key use cases for AI in cardiologyScaling expertise with BeatLogicDemocratizing Expertise with Avigo PlusPredicting outcomes with HeartlogicAI transforms raw data into actionable insights that improve patient outcomes.Radiology and cardiology are examples of how AI enhances (not replaces) medical professionals.Clinicians who embrace AI will outperform those who don't.Ongoing education on AI's role, limits, and evidence base is crucial for healthcare providers.A Little About Kenneth:Kenneth Stein is senior vice president and global chief medical officer at Boston Scientific. In this role, he has oversight for the clinical trials, medical safety and medical affairs functions and is responsible for ensuring a cohesive clinical community of practice across the company. Prior to Boston Scientific, Stein held the position of associate director of clinical cardiac electrophysiology at Weill Cornell Medical Center and associate professor of medicine at Cornell University. Stein is a graduate of Harvard College (in economics) and New York University School of Medicine. He is widely published, having authored more than 160 papers in the peer reviewed medical literature.  

Gridiron Report: Cardiac Bears Pull Off Another Late Comeback full 144 Mon, 17 Nov 2025 15:26:32 +0000 bDMmk1XDQr1fno2oUr5VGXhBVxWiACuT news Chicago All Local news Gridiron Report: Cardiac Bears Pull Off Another Late Comeback A dive into the top headlines in Chicago, delivering the news you need in 10 minutes or less multiple times a day from WBBM Newsradio. 2024 © 2021 Audacy, Inc. News False https://player.amperwavepodcast

We would love to hear from you! Please send us your comments here. --------This Christmas, you can shine the light of Christ into places of darkness and pain with a purchase from the Joni and Friends Christmas catalog. You are sending hope and practical care to people with disabilities, all in the name of Jesus! Thank you for listening! Your support of Joni and Friends helps make this show possible. Joni and Friends envisions a world where every person with a disability finds hope, dignity, and their place in the body of Christ. Become part of the global movement today at www.joniandfriends.org. Find more encouragement on Instagram, TikTok, Facebook, and YouTube.

This Week your hosts Hall of Fame ref JHawk, JGold & Charly Butters discuss Jgolds dinner, who will have a cardiac event first, making sloppy steaks, Butters doing Whatnot for Monsters in the Toybox for the first time. JGold is going to the PWJunkie show this weekend and as a special game this week the boys use the PWI Women's 250 to draft 10 talents each that will be put into a tournament to crown a winner! Then they review the West Coast Pro/ Prestige show "Strength Beyond Strength" and so much more!

Time to get up with a Steelers stinker! Rodgers roasted on the coast! Are the playoffs a pipe dream for Pittsburgh? Smart money says yes! Meanwhile - a Miami Meltdown - do Josh and the Bills shuffle back to Buffalo locked out in the AFC East? And - oh Cardiac Caleb is clutch! The Bears bounce back again - what did their comeback mean for them, and the coach on the other side?! Learn more about your ad choices. Visit podcastchoices.com/adchoices

Beta-blockers offer no survival benefit for most heart attack patients with normal heart function, even though they're still widely prescribed Women face higher risks on beta-blockers, including nearly double the risk of death when given higher doses, while men show no measurable harm or benefit Side effects such as fatigue, dizziness, depression, and sexual dysfunction often burden patients without providing meaningful protection The real root of heart disease lies in damaged mitochondria, which are overwhelmed by linoleic acid (LA) from vegetable oils found in most processed foods You can protect your heart by reducing LA, eating the right kinds of carbohydrates, walking daily, getting safe sunlight, and tracking your HOMA-IR score